EP
ACOR

Elkfork Partners’s Acorda Therapeutics ACOR Stock Holding History

Elkfork Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-74
Closed -$68K – 1073
2019
Q2 		$68K Buy
74
+17
+30% +$20.9K ﹤0.01% 985
2019
Q1 		$91K Hold
57
– – ﹤0.01% 929
2018
Q4 		$107K Hold
57
– – ﹤0.01% 886
2018
Q3 		$135K Hold
57
– – ﹤0.01% 914
2018
Q2 		$197K Hold
57
– – 0.01% 803
2018
Q1 		$162K Hold
57
– – ﹤0.01% 844
2017
Q4 		$147K Buy
57
+20
+54% +$56.9K ﹤0.01% 861
2017
Q3 		$104K Buy
37
+7
+23% +$18.4K ﹤0.01% 890
2017
Q2 		$71K Buy
30
+14
+88% +$27.7K ﹤0.01% 934
2017
Q1 		$40K Buy
16
+1
+7% +$2.88K ﹤0.01% 944
2016
Q4 		$34K Buy
+15
New +$35.7K ﹤0.01% 933

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elkfork Partners's ACOR Position: Q3 2019 in Review

Elkfork Partners sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 74 shares — an estimated $68K sold.

Elkfork Partners first reported a position in ACOR in Q4 2016 and held it in 11 quarters. The position peaked at $197K in Q2 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • Elkfork Partners reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Elkfork Partners sold 74 Acorda Therapeutics shares in Q3 2019, an estimated $68K.
  • Elkfork Partners first reported a position in Acorda Therapeutics in Q4 2016 and held it in 11 quarters.
  • Elkfork Partners's Acorda Therapeutics position peaked at $197K in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.